Incretin-based therapies: where will we be 50 years from now?

Diabetologia

Volumn 58, Issue 8, 2015, Pages 1745-1750

  Meier, Juris J ^a   Nauck, Michael A ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

GIP; GLP 1; Gut hormones; Type 2 diabetes

Indexed keywords

CHOLECYSTOKININ; DIPEPTIDYL PEPTIDASE IV INHIBITOR; G PROTEIN COUPLED RECEPTOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INCRETIN; INSULIN; PEPTIDE YY; VASOACTIVE INTESTINAL POLYPEPTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

BARIATRIC SURGERY; EDITORIAL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL RESEARCH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; OSMOTIC MINIPUMP; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; AGONISTS; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS;

EID: 84937519442     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3608-6     Document Type: Editorial

References (22)

1. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29:46–54
2. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ (2001) Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 50:1588–1597
3. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744
4. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742
5. Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diab Endocrinol 2:885–893
6. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124:S3–S18
7. Nauck MA, Baranov O, Ritzel RA, Meier JJ (2013) Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Diabetologia 56:1878–1883
8. Tahrani AA, Bailey CJ, Del Prato S, Barnett AH (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378:182–197
9. Madsbad S, Holst JJ (2014) GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes 63:3172–3174
10. Meier JJ, Nauck MA (2004) Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide. Best Pract Res Clin Endocrinol Metab 18:587–606
11. Meier JJ, Nauck MA (2004) GIP as a potential therapeutic agent? Horm Metab Res 36:859–866
12. Finan B, Yang B, Ottaway N et al (2015) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21:27–36
13. Nauck MA, Meier JJ (2008) Incretins and regulation of insulin secretion. In: Seino S, Bell GI (eds) Pancreatic beta cell in health and disease. Springer, Tokyo, pp 335–378
14. Madsbad S, Dirksen C, Holst JJ (2014) Mechanisms of changes in glucose metabolism and bodyweight after bariatric surgery. Lancet Diab Endocrinol 2:152–164
15. Mingrone G, Panunzi S, De Gaetano A et al (2012) Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 366:1577–1585
16. Koehler JA, Baggio LL, Yusta B et al (2015) GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 21:379–391
17. Astrup A, Rossner S, Van Gaal L et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606–1616
18. Utzschneider KM, Tong J, Montgomery B et al (2008) The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 31:108–113
19. Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 37:1443–1451
20. Kielgast U, Krarup T, Holst JJ, Madsbad S (2011) Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function. Diabetes Care 34:1463–1468
21. Ussher JR, Drucker DJ (2014) Cardiovascular actions of incretin-based therapies. Circ Res 114:1788–1803
22. Aviles-Olmos I, Dickson J, Kefalopoulou Z et al (2013) Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest 123:2730–2736